A new AI-designed drug may hold to the potential cure for inflammatory bowel disease, according to a new study.
An AI-driven drug discovery and development company, Insilico Medicine (‘Insilico’) on 8 January announced the positive results from two Phase I studies in Australia and China with the drug.
Results showed that ISM5411 was generally safe and well tolerated across all dose groups in both countries.
An AI breakthrough
The drug known as ISM5411 is a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 for Inflammatory Bowel Disease (IBD).
The two phase I studies were conducted simultaneously in Australia and China to test its safety, tolerability, pharmacokinetics (PK), and food effects (FE).
Tests were conducted using single ascending dose (SAD), multiple ascending dose (MAD) and FE parts involving 76 healthy subjects in Australia and 48 healthy subjects in China, and the drug was found to be safe and well tolerated.
Philip Ryan, MD, PhD, the Principal Investigator of ISM5411 Phase I study in Australia said:
“It is pleasing to see the good safety and PK profiles of ISM5411, especially the low systemic exposure across all dose groups.These results are suggestive of the gut-restrictive property of ISM5411 and good potential for further clinical development.”
In addition, there were no serious adverse side effects leading to discontinued treatments, while overall occurrence rate of treatment-emergent adverse events (TEAEs) was similar between all treatment groups and pooled placebo groups in both studies.
Because of the success, the company is taking the test into the next stage, which is patient trials to see how quickly the treatment can be made available for use.
“As an advanced technology, AI has played important roles in drug discovery and clinical research. We are looking forward to following ISM5411 as it progresses into patient trials, where we hope to see clinical benefits stemming from this technology.”
Up to this point, treatment for IBD has focused on anti-inflammatory strategies, but this new AI-designed drug focuses on both stopping inflammation and initiating tissue repair.
ReadNext
